Kamada Ltd. announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S. for KEDRAB(R) (R babies Immune Globulin [Human), which is indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. The current agreement now extends through March 2026, and the companies are in discussions to potentially further expand the scope of the collaboration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,000 ILa | -2.91% | -4.03% | -10.19% |
May. 08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.19% | 311M | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- KMDA Stock
- News Kamada Ltd.
- Kamada Ltd. Announces Kedrion Exercised Its Option for Two-Year Extension of Kedrion Distribution Agreement in the U.S